Provided by Tiger Fintech (Singapore) Pte. Ltd.

Charles River Laboratories

161.84
+7.304.72%
Post-market: 161.840.00000.00%17:53 EDT
Volume:1.25M
Turnover:203.50M
Market Cap:7.96B
PE:-117.74
High:164.58
Open:155.95
Low:154.79
Close:154.54
52wk High:230.02
52wk Low:91.86
Shares:49.21M
Float Shares:48.62M
Volume Ratio:1.90
T/O Rate:2.58%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3746
EPS(LYR):0.2004
ROE:-1.81%
ROA:4.31%
PB:2.38
PE(LYR):807.55

Loading ...

Charles River Laboratories International Inc. Stock Slips 3.2%, Underperforms Competitors

Dow Jones
·
Aug 22

Joseph W. LaPlume, EVP of Corp Strategy & Development, Reports Disposal of Common Shares in Charles River Laboratories International Inc

Reuters
·
Aug 21

FACTBOX-Healthcare firms see growing activist investor involvement in the past year

Reuters
·
Aug 20

PTC Therapeutics Faces FDA Rejection On Rare Disease Treatment Over Efficacy Concerns

Benzinga
·
Aug 19

RBC says PTC Therapeutics CRL may signal difficulty for Biohaven

TIPRANKS
·
Aug 19

PTC Therapeutics CRL ‘expected,’ focus moves to Sephience, says RBC Capital

TIPRANKS
·
Aug 19

Minerva Neurosciences Provides Business Updates and Second Quarter Financial Results

GlobeNewswire
·
Aug 15

Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2025 and Provides Corporate Update

GlobeNewswire
·
Aug 14

Unicycive Therapeutics requests Type A meeting with FDA to discuss CRL

TIPRANKS
·
Aug 14

Applied Therapeutics Reports Q2 Loss

Motley Fool
·
Aug 14

Charles River Laboratories International Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Aug 13

Milestone Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Regulatory and Corporate Update

GlobeNewswire
·
Aug 12

Joseph W. LaPlume, EVP of Corp Strategy & Develop, Reports Disposal of Charles River Laboratories Common Shares

Reuters
·
Aug 09

J.P. Morgan Reaffirms Their Hold Rating on Charles River Labs (CRL)

TIPRANKS
·
Aug 08

Evercore ISI Sticks to Their Buy Rating for Charles River Labs (CRL)

TIPRANKS
·
Aug 08

Charles River Labs Is Maintained at Equal-Weight by Barclays

Dow Jones
·
Aug 07

Replimune Reports Fiscal First Quarter 2026 Financial Results and Provides Corporate Update

GlobeNewswire
·
Aug 07

Barclays Keeps Their Hold Rating on Charles River Labs (CRL)

TIPRANKS
·
Aug 07

Charles River profit forecast clouded by order cancellations from biotechs

Reuters
·
Aug 07

Charles River price target raised to $175 from $170 at BofA

TIPRANKS
·
Aug 07